296 related articles for article (PubMed ID: 30696697)
1.
Colebatch AJ; Dobrovic A; Cooper WA
J Clin Pathol; 2019 Apr; 72(4):281-284. PubMed ID: 30696697
[TBL] [Abstract][Full Text] [Related]
2. Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.
Günes C; Wezel F; Southgate J; Bolenz C
Nat Rev Urol; 2018 Jun; 15(6):386-393. PubMed ID: 29599449
[TBL] [Abstract][Full Text] [Related]
3. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
4. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Nault JC; Calderaro J; Di Tommaso L; Balabaud C; Zafrani ES; Bioulac-Sage P; Roncalli M; Zucman-Rossi J
Hepatology; 2014 Dec; 60(6):1983-92. PubMed ID: 25123086
[TBL] [Abstract][Full Text] [Related]
5. Frequency of TERT promoter mutations in human cancers.
Vinagre J; Almeida A; Pópulo H; Batista R; Lyra J; Pinto V; Coelho R; Celestino R; Prazeres H; Lima L; Melo M; da Rocha AG; Preto A; Castro P; Castro L; Pardal F; Lopes JM; Santos LL; Reis RM; Cameselle-Teijeiro J; Sobrinho-Simões M; Lima J; Máximo V; Soares P
Nat Commun; 2013; 4():2185. PubMed ID: 23887589
[TBL] [Abstract][Full Text] [Related]
6. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer.
Li C; Wu S; Wang H; Bi X; Yang Z; Du Y; He L; Cai Z; Wang J; Fan Z
Oncotarget; 2015 Aug; 6(23):19542-51. PubMed ID: 26143634
[TBL] [Abstract][Full Text] [Related]
7. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Borah S; Xi L; Zaug AJ; Powell NM; Dancik GM; Cohen SB; Costello JC; Theodorescu D; Cech TR
Science; 2015 Feb; 347(6225):1006-10. PubMed ID: 25722414
[TBL] [Abstract][Full Text] [Related]
8. An interaction proteomics survey of transcription factor binding at recurrent TERT promoter mutations.
Makowski MM; Willems E; Fang J; Choi J; Zhang T; Jansen PW; Brown KM; Vermeulen M
Proteomics; 2016 Feb; 16(3):417-26. PubMed ID: 26553150
[TBL] [Abstract][Full Text] [Related]
9. TERT biology and function in cancer: beyond immortalisation.
Pestana A; Vinagre J; Sobrinho-Simões M; Soares P
J Mol Endocrinol; 2017 Feb; 58(2):R129-R146. PubMed ID: 28057768
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players.
Yuan X; Larsson C; Xu D
Oncogene; 2019 Aug; 38(34):6172-6183. PubMed ID: 31285550
[TBL] [Abstract][Full Text] [Related]
11. Telomerase reactivation in cancers: Mechanisms that govern transcriptional activation of the wild-type vs. mutant TERT promoters.
Li Y; Tergaonkar V
Transcription; 2016 Mar; 7(2):44-9. PubMed ID: 27028424
[TBL] [Abstract][Full Text] [Related]
12. DNA methylation of the TERT promoter and its impact on human cancer.
Lee DD; Komosa M; Nunes NM; Tabori U
Curr Opin Genet Dev; 2020 Feb; 60():17-24. PubMed ID: 32114294
[TBL] [Abstract][Full Text] [Related]
13. CEBP factors regulate telomerase reverse transcriptase promoter activity in whey acidic protein-T mice during mammary carcinogenesis.
Kumar M; Witt B; Knippschild U; Koch S; Meena JK; Heinlein C; Weise JM; Krepulat F; Kuchenbauer F; Iben S; Rudolph KL; Deppert W; Günes C
Int J Cancer; 2013 May; 132(9):2032-43. PubMed ID: 23023397
[TBL] [Abstract][Full Text] [Related]
14. Telomerase Biology Associations Offer Keys to Cancer and Aging Therapeutics.
Smith-Sonneborn J
Curr Aging Sci; 2020; 13(1):11-21. PubMed ID: 31544708
[TBL] [Abstract][Full Text] [Related]
15. TERT Promoter Mutations Enhance Telomerase Activation by Long-Range Chromatin Interactions.
Min J; Shay JW
Cancer Discov; 2016 Nov; 6(11):1212-1214. PubMed ID: 27807101
[TBL] [Abstract][Full Text] [Related]
16. Reactivation of telomerase in cancer.
Akincilar SC; Unal B; Tergaonkar V
Cell Mol Life Sci; 2016 Apr; 73(8):1659-70. PubMed ID: 26846696
[TBL] [Abstract][Full Text] [Related]
17. Understanding TERT Promoter Mutations: A Common Path to Immortality.
Bell RJ; Rube HT; Xavier-Magalhães A; Costa BM; Mancini A; Song JS; Costello JF
Mol Cancer Res; 2016 Apr; 14(4):315-23. PubMed ID: 26941407
[TBL] [Abstract][Full Text] [Related]
18. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
Cevik D; Yildiz G; Ozturk M
World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
[TBL] [Abstract][Full Text] [Related]
19. Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells.
Liu Z; Li Q; Li K; Chen L; Li W; Hou M; Liu T; Yang J; Lindvall C; Björkholm M; Jia J; Xu D
Oncogene; 2013 Sep; 32(36):4203-13. PubMed ID: 23045275
[TBL] [Abstract][Full Text] [Related]
20. TERT promoter mutations and telomeres during tumorigenesis.
Lorbeer FK; Hockemeyer D
Curr Opin Genet Dev; 2020 Feb; 60():56-62. PubMed ID: 32163830
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]